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Preface 
I worked with Dr. Julie Dumond and colleagues to study the function of cytokines to 
aging, antiretroviral drugs, and endogenous nucleotide exposures in HIV-infected 
subjects. My involvements in the study include participating in subject recruitment and 
visit, assisting in AUC calculations, conducting literature searches, and contributing to 
manuscript write-up. The manuscript fully describes the study and is prepared for 
publication in HIV Medicine journal. 
 
Abstract 
Objectives: It was recently found that p16INK4a, a marker for aging and cellular 
senescence, is associated with lower intracellular concentrations of endogenous 
nucleotides and nucleos(t)ide reverse transcriptase inhibitors (NRTIs). This study 
expands on these findings by determining whether markers of inflammation are 
predictive of p16INK4a expression, intracellular metabolite exposure, or endogenous 
nucleotide concentrations. 
Methods: Samples from HIV-infected adults receiving daily tenofovir/emtricitabine 
(TFV/FTC) with either efavirenz (EFV) or atazanavir/ritonavir (ATV/r) were tested for 
p16INK4a expression, plasma cytokine concentrations, and intracellular drug 
concentrations. Elastic net regression was used to identify cytokines that were 
predictive of p16INK4a expression and intracellular metabolite/endogenous nucleotide 
exposures. These outcomes were each compared between groups with detectable 
versus undetectable levels of predictive cytokines using a Wilcoxon rank-sum test.  
Results: Enrolled participants had a median age of 48 years (range 23 - 73). Results of 
the elastic net regression determined that individuals with detectable interleukin-6 (IL-6) 
concentrations were predicted to have elevated p16INK4a expression and lower exposure 
to tenofovir diphosphate (TFV-dp), emtricitabine triphosphate (FTC-tp), and their 
respective endogenous nucleotides, deoxyadenosine triphosphate (dATP) and 
deoxycytidine triphosphate (dCTP).  
Conclusions: Elevated concentrations of IL-6 have been associated with frailty, 
morbidity, and mortality in individuals with HIV. Our findings suggest that IL-6 affects 
cellular senescence, NRTI pharmacokinetics, and endogenous nucleotide pools in an 
aging HIV population. 
 
Introduction 
Despite recent advances in antiretroviral (ARV) therapy, HIV-infected patients are at 
heightened risk for developing complications typically associated with increased age (1). 
Markers of inflammation are chronically elevated in HIV-infected patients and have been 
associated with increases in non-AIDS defining morbidity and all-cause mortality (2,3). 
Given these consequences, understanding the role inflammation plays in the 
pharmacokinetics of ARVs and the progression of HIV is critical to improving outcomes 
in aging patients. 
Tenofovir and emtricitabine are nucleos(t)ide reverse transcriptase inhibitors (NRTIs) 
and are recommended in first-line combination ARV therapies. In order to exert their 
antiviral effect, they must cross the cellular membrane and undergo phosphorylation to 
their respective metabolites, tenofovir diphosphate (TFV-dp) and emtricitabine 
triphosphate (FTC-tp). They work by competing with endogenous nucleotides 
(deoxyadenosine triphosphate [dATP] for TFV-dp; deoxycytidine triphosphate [dCTP] 
for FTC-tp) for incorporation into the DNA of infected cells, leading to chain termination. 
By virtue of this mechanism, it is thought that the ratio of intracellular metabolite to 
endogenous nucleotide has a greater influence on antiviral efficacy and toxicity than 
intracellular drug concentrations alone (4).  
We previously demonstrated that increased expression of p16INK4a, a biomarker for 
aging, is associated with lower concentrations of TFV/FTC intracellular metabolites and 
endogenous nucleotides (5). The work herein extends upon that study and aims to 
determine whether markers of inflammation previously associated with aging and HIV 
morbidity / mortality are predictive of p16INK4a expression, intracellular metabolite 
exposure, or endogenous nucleotide concentrations.  
 
Methods 
Clinical Trial Design 
A detailed description of the trial design and eligibility criteria has been previously 
published (5). In short, HIV-infected adults were recruited from UNC HealthCare 
Infectious Diseases Clinic (Chapel Hill, NC) and the Cone Health Regional Center for 
Infectious Diseases (Greensboro, NC). All participants received daily TFV/FTC 300/200 
mg with either efavirenz 600mg or atazanavir/ritonavir 300/200mg for at least 2 weeks. 
Eligible participants had four blood samples taken (predose, 2, 4-6, 10-14 hours). The 
study protocol was approved by the Institutional Review Boards of both institutions 
(Clinicaltrials.gov NCT01180075). 
Cytokines 
At one of the above pharmacokinetic time points, an additional EDTA tube was 
collected, centrifuged at 3000 RPMs for 10 minutes, and stored at -80ºC for biomarker 
profiling. Analysis was performed in the Duke Regional Biocontainment Laboratory 
(RBL) Immunology Unit (Durham, NC) under the direction of Dr. Gregory D. Sempowski 
using MILLIPLEX® MAP Human Cytokine/Chemokine Premixed 39 Plex bead-based 
assay kit (EMD Millipore Corporation, Billerica, Massachusetts). Due to the large 
number of potential predictor variables, a subset of cytokines that have been associated 
with HIV and aging was included in the analysis: TNFα, IFNγ, IL-1ra, IL-6, IL-12P40, IL-
12P70, IL-17α, MCP-1, MIP-1α, MIP-1β, MCP-3, MDC, GRO, sCD40L, fractalkine, and 
eotaxin (6–8). 
Pharmacokinetics & p16INK4a Expression 
TFV-dp, FTC-tp, dATP, and dCTP concentrations in peripheral blood mononuclear cells 
(PBMCs) were measured using LC-MS/MS in the UNC Center for AIDS Research 
Clinical Pharmacology and Analytical Chemistry Laboratory (5). Drug exposure was 
measured as area under the curve (AUC) using non-compartmental analysis in Phoenix 
Win Nonlin 6.3 (Pharsight, A Certara Company, St. Louis, MO); the linear up/log down 
trapezoidal method was used to calculate AUC over the dosing interval. Expression of 
p16INK4a was determined using validated PCR-based methods (9) and final values were 
log2-transformed. 
Statistical Analysis 
The primary goal for this analysis was to identify cytokines that are predictive of p16INK4a 
expression and intracellular metabolite/endogenous nucleotide AUCs. Predictor 
variables were selected using a general linear model elastic net algorithm, a penalized 
regression technique (10) capable of selecting variables that are most predictive 
amongst a large number of correlated potential predictors. Tuning parameters for the 
elastic net algorithm were chosen via 5-fold cross-validation with the optimal tuning 
parameter values chosen to minimize predicted residual sum of squares (CVPRESS). 
The cytokine levels were dichotomized as detectable (1) or undetectable (0) for 
analysis. Chronological age in years was included as a potential predictor variable. An 
exact Wilcoxon rank-sum test was used to assess whether p16INK4a expression and 
intracellular metabolite/endogenous nucleotide exposures were different between 
groups with detectable and undetectable concentrations of predictive cytokines. 
Analyses were conducted in SAS version 9.4 (SAS Institute, Cary, NC) using the 
GLMSELECT procedure or R 3.1.2 (r-project.org). A p-value of < 0.05 was considered 
statistically significant. These analyses were exploratory in nature, so no adjustment 
was made for multiple comparisons. 
 
 
 
 
Results 
Study Participants 
The study enrolled 79 participants receiving TFV/FTC. Of those, 54 were receiving EFV 
and 25 were receiving ATV/r. The median age was 48 years (range 23 - 73) and the 
median duration of HIV infection was 10 years. Sixty-one percent of participants were 
African-American. Detailed demographics of the study population have been published 
(5). One enrolled participant did not have a sample available for cytokine profiling. Of 
the remaining 78, five did not provide a sample for p16INK4a measurement and six did 
not provide adequate samples for accurate calculation of intracellular 
metabolite/endogenous nucleotide exposures. These individuals were excluded from 
analysis. 
Elastic Net Analysis 
P16INK4a expression and AUC measurements were available for 73 and 72 participants, 
respectively. Table 1 presents the elastic net results for p16INK4a expression and the four 
AUC measures using dichotomized cytokine predictor variables. Detectable 
concentrations of interleukin-6 (IL-6) were found to be associated with higher p16INK4a 
expression and lower AUC of FTC-tp, TFV-dp, dATP, and dCTP. Macrophage 
inflammatory protein-1β (MIP-1β) was negatively associated with p16INK4a expression 
and positively associated with dCTP exposure. Monocyte chemoattractant protein 3 
(MCP-3) was associated with lower TFV-dp exposure. Age positively predicted p16INK4a 
expression, which has been previously observed (11). 
Cytokines were dichotomized based on detectability because a sizeable proportion of 
raw concentration values were left censored. The R2 values for the optimal model are 
presented for each outcome and represent the proportion of variation explained by 
predictor variables in the model. The penalized parameter estimates for the selected 
variables describe the direction of prediction. The magnitude does not provide for 
meaningful comparisons between models and significance testing cannot be applied to 
the model parameters as in ordinary least squares (10). 
Outcomes of interest were then compared between groups with detectable and 
undetectable concentrations of IL-6. Figure 1 shows that participants with detectable 
concentrations of IL-6 had significantly higher p16INK4a expression and lower TFV-dp, 
FTC-tp, dATP, and dCTP exposures in PBMCs. Means and standard deviations are 
provided in Table 2. Comparisons between groups with detectable and undetectable 
concentrations of MIP-1β and MCP-3 were not statistically significant (Wilcoxon p > 
0.05). 
 
Discussion 
Results from the elastic net regression showed detectable concentrations of IL-6 
predicted increased expression of p16INK4a. PIM-1 is a proto-oncogene expressed in the 
hematopoietic and lymphoid system. It encodes for a serine/threonine protein kinase 
that regulates cell cycle progression and apoptosis (12). IL-6 mediates PIM-1 
expression through signal transducer and activator of transcription-3 (STAT3), an 
important transcription factor in cytokine signaling pathways (13). Overexpression on 
PIM-1 increases markers of aging and cellular senescence, including p16INK4a. The 
relationship between IL-6 and p16INK4a seen in our HIV positive cohort could be 
explained by through this mechanism. 
It was also observed that participants with detectable IL-6 had decreased exposure to 
TFV-dp and FTC-tp. This finding could be explained by membrane transporter 
modulation. TFV is a known substrate for efflux transporters P-glycoprotein (P-gp) and 
breast cancer resistance protein (BCRP), and FTC is transported by multidrug 
resistance-associated protein-1 (MRP-1) (14). IL-6 has been shown to directly increase 
P-gp and BCRP cell-surface expression through the PIM-1 pathway (15) and MRP-1 
expression through unknown mechanisms in human cells lines (16). Modulation of 
membrane transporters is already known to affect intracellular accumulation of protease 
inhibitors (17). Increased expression of these efflux transporters on PBMCs could result 
in decreased intracellular NRTI concentrations. 
Detectable concentrations of IL-6 were also predictive of lower amounts of dATP and 
dCTP. Reduced exposure to these nucleotides may be related to cell cycle arrest in 
senescent cells. Demand for nucleotide biosynthesis varies during the cell cycle and is 
highest during S-phase (Bayes, et al. 2014). To meet this heightened demand, enzymes 
involved in the synthesis of nucleotides and deoxynucleotides, such as phosphoribosyl 
pyrophosphate (PRPP) and ribonucleotide reductase (RNR), are upregulated (18). IL-6 
has been described to induce premature senescence in human fibroblasts (19). Since 
senescent cells are arrested in the G-1 phase and are no longer dividing, demand for 
endogenous nucleotides, such as dATP and dCTP, remains low and their synthesis is 
attenuated.   
MIP-1β was selected as a predictor of p16INK4a expression and dCTP AUC. MCP-3 was 
predictive of TFV-dp exposure. However, it was decided to focus on IL-6, as it was 
consistently predictive of all outcomes of interest. 
The results from this work are consistent with our earlier findings. P16INK4a was found to 
be negatively associated with drug metabolite and endogenous nucleotide exposures. 
Our analysis demonstrated that detectable concentrations of IL-6 are positively 
predictive of p16INK4a expression, while negatively predictive of intracellular drug 
metabolite and nucleotide exposures. This relationship suggests that cytokines, such as 
IL-6, could play a role in the inverse association between p16INK4a expression and 
drug/nucleotide exposure previously seen. 
Also, although a relationship between IL-6 and intracellular metabolite/endogenous 
nucleotide exposures is evident, our study lacks the ability to identity a clear causal 
mechanism for the relationships being seen. Future in vitro and in vivo studies are 
planned to confirm these relationships and explore potential mechanisms. 
HIV-infected patients exhibit significantly higher plasma concentrations of IL-6 
compared to uninfected controls (20) and IL-6 has been associated with increased all-
cause mortality in this population (2). The results of this study suggest that IL-6 affects 
cellular senescence, NRTI pharmacokinetics, and endogenous nucleotide pools. These 
findings emphasize the importance that markers of inflammation play in the treatment of 
HIV in an aging population, and further support the idea of cytokines as potential drug 
targets. 
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Figure and Tables 
 
 
Figure 1: Boxplots showing the distributions of a) p16INK4a expression, b) TFV-dp 
AUC, c) FTC-tp AUC, d) dATP AUC, and e) dCTP AUC between participants with 
undetectable (0) and detectable (1) levels of IL-6. 
Each box corresponds to the inter-quartile range (middle 50% of observations) for the 
group. The median is indicated by the horizontal line within the box. The distance 
between the upper and lower whiskers represents the range of the data that are not 
considered outliers. Outliers are denoted by a closed circle (•). Participants with 
detectable concentrations of IL-6 exhibited significantly higher expression of p16INK4a 
than those with undetectable concentrations (a). Conversely, participants with 
detectable IL-6 concentrations had a lower TFV-dp AUC (b), FTC-tp AUC (c), dATP 
AUC (d), and dCTP AUC (e). ** p <0.01, *** p < 0.001 
AUC, area under the curve; TFV-dp, tenofovir diphosphate; FTC-tp, emtricitabine 
triphosphate; dATP, deoxyadenosine triphosphate; dCTP, deoxycytidine triphosphate, 
IL-6, interleukin-6. 
 
 
 
 
 
Outcome N R2 Predictor Variable 
Parameter 
Estimate 
p16INK4a 73  0.1937  Intercept 1.318  
   IL-6 0.459  
   MIP-1β -0.258  
   Age (years) 0.011 
TFV-dp AUC  72  0.1131  Intercept 5254.5  
   IL-6 -1707.5  
   MCP-3  -212.4  
FTC-tp AUC  72  0.1242  Intercept 184812  
   IL-6 -57829  
dATP AUC  72  0.1695  Intercept 5089.1  
   IL-6 -1423.6  
dCTP AUC  72 0.1676  Intercept 17085  
   IL-6 -5895.7  
   MIP-1β 834.5  
 
Table 1: Elastic net results using dichotomized cytokine values as predictor 
variables for p16INK4a expression, TFV-dp AUC, FTC-tp AUC, dATP AUC, and dCTP 
AUC.  
The R2 value is the proportion of variation explained by predictor variables in the model. 
Variables chosen by the elastic net algorithm that best predict each outcome are shown 
with their corresponding penalized parameter estimates. The penalized parameter 
estimates show whether a variable is positively or negatively predictive of the outcome. 
Detectable concentrations of IL-6 are positively predictive of p16INK4a expression and 
negatively predictive of TFV-dp AUC, FTC-tp AUC, dATP AUC, and dCTP AUC. 
Detectable concentrations of MIP-1β predict p16INK4a expression and dCTP AUC. 
Detectable MCP-3 is a predictor for TFV-dp AUC. 
AUC, area under curve; TFV-dp tenofovir diphosphate; FTC-tp, emtricitabine 
triphosphate; dATP, deoxyadenosine triphosphate; dCTP, deoxycytidine triphosphate. 
 
 
 
 
Undetectable IL-6  
(n=16) 
Detectable IL-6  
(n=57) 
Log2p16INK4a 1.50 + 0.69 2.05 + 0.59 
TFV-dp AUC (ug*h/L) 6290 + 6408 2022 + 3079 
FTC-tp AUC (ug*h/L) 1.99x105 + 8.2x 104 1.22x105 + 8.3x 104 
dATP AUC (fmol*h/106 cells) 6502 + 1981 3518 + 1777 
dCTP AUC (fmol*h/106 cells) 1.93x104 + 7180 1.15x104 + 7251 
 
Table 2: Comparison of p16INK4a expression, TFV-dp AUC, FTC-tp AUC, dATP 
AUC, and dCTP AUC measurements between participants with undetectable and 
detectable concentrations of IL-6.  
Values are reported as mean + standard deviation.   
AUC, area under the curve; TFV-dp, tenofovir diphosphate; FTC-tp, emtricitabine 
triphosphate; dATP, deoxyadenosine triphosphate; dCTP, deoxycytidine triphosphate, 
IL-6, interleukin-6. 
 	
